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Kidney cellsDiosmetin (DIOS) is a ﬂavone aglycone commonly occurring in citrus species and olive leaves, in addition
it is one of the active ingredients of some medications. Based on both in vitro and in vivo studies several
beneﬁcial effects are attributed to DIOS but the biochemical background of its action seems to be complex
and it has not been completely explored yet. Previous investigations suggest that most of the ﬂavonoid
aglycones have negative effect on ATP synthesis in a dose dependent manner. In our study 17 ﬂavonoids
were tested and interestingly DIOS caused a signiﬁcant elevation of intracellular ATP levels after 6- and
12-h incubation in MDCK kidney cells. In order to understand the mechanism of action, intracellular ATP
and protein levels, ATP/ADP ratio, cell viability and ROS levels were determined after DIOS treatment. In
addition, impacts of different enzyme inhibitors and effect of DIOS on isolated rat liver mitochondria
were also tested. Finally, the inﬂuence of DIOS on the ATP depleting effect of the mycotoxin, ochratoxin
A was also investigated. Our major conclusions are the followings: DIOS increases intracellular ATP levels
both in kidney and in liver cells. Inhibition of glycolysis or citric acid cycle does not decrease the observed
effect. DIOS-induced elevation of ATP levels is completely abolished by the inhibition of ATP synthase.
DIOS is able to completely reverse the ATP-depleting effect of the mycotoxin, ochratoxin A. Most probably
the DIOS-induced impact on ATP system does not originate from the antioxidant property of DIOS. Based
on our ﬁndings DIOS may be promising agent to positively inﬂuence ATP depletion caused by some
metabolic poisons.
 2014 Elsevier B.V. All rights reserved.1. Introduction
Flavonoids are natural polyphenols with well-known antioxi-
dant and scavenger characteristics [1]. Furthermore, ﬂavonoids
show cytoprotective effects and are considered to be promising
agents in prevention and/or therapy of numerous disorders [1–4].
Previous studies highlighted that besides their scavenger property
ﬂavonoids exerted inﬂuence on the activity of several enzymes,
transporters and on cell signaling pathways [1]. Interestingly,
based on our current knowledge all of the previous investigations
suggested that at least some of the studied ﬂavonoids were able
to decrease intracellular ATP levels [5–9]. Chinnam et al. described
the inhibition of Escherichia coli (E. coli) ATP synthase on puriﬁed F1subunit or membrane bound F1Fo complexes related to different
dietary bioﬂavonoids [5]. Li et al. observed similar inhibitory effect
of theaﬂavins on E. coli ATP synthase [6]: They suggested the F1
part as the primary site of inhibition and they also reported the
inhibition of electron transport chain. In another study, Kanno
et al. found naringenin-induced signiﬁcant decrease of intracellular
ATP levels and increased dose-dependent hyperpolarization of
mitochondrial membrane potential in HL-60 cells [7]. Moreover,
Mathiesen et al. and Dorta et al. reported uncoupled oxidative
phosphorylation due to C-methylated ﬂavonoids [8] and substan-
tial respiratory chain inhibition by quercetin and galangin [9] in
rat liver mitochondria. In our literature survey we have not found
any references observing that certain ﬂavonoids might increase
intracellular ATP levels.
Diosmetin (DIOS; Fig. 1) is a ﬂavone aglycone occurring mainly
in citrus species (and also in related products e.g. lemon or
bergamot juices) and in olive (Olea europaea L.) leaves [10–14].
Fig. 1. Chemical structure of the studied ﬂavone (acacetin, apigenin, baicalein, chrysin, diosmetin, ﬂavone, luteolin), ﬂavonol (ﬁsetin, galangin, morin, myricetin, quercetin),
ﬂavanone (hesperetin, naringenin), ﬂavanol (catechin) and isoﬂavone (daidzein, genistein) aglycones.
2 M. Poór et al. / Journal of Photochemistry and Photobiology B: Biology 132 (2014) 1–9Furthermore, it is widely known that the glycoside of diosmetin
called diosmin is the active ingredient of various vasoprotective
medications, for example Detralex or Daﬂon (containing 450
mg diosmin) [15,16], which are capillary stabilizing agents. In addi-
tion, there have been described several other positive effects attrib-
uted to diosmin in recently published studies both in vitro and
in vivo, indicating a complexmechanism of action [17–22]. Previous
pharmacokinetic investigations showed that only the aglycone
DIOS can enter the bloodstream (no diosmin was detected in pat-
ent’s blood plasma) [23,24]. After administration of 450 mg oral
dose of diosmin, about 1.0–1.5 lM peak concentrations of DIOS
were reported in the plasma (studied in healthy human volunteers)
[24]. The above listed facts support that additional investigations
are needed to explore further potential biochemical effects of DIOS.
The mycotoxin, ochratoxin A (OTA) is a widely spread food
contaminant [25,26]. Principally nephrotoxic and carcinogenic
effects are attributed to OTA but several other adverse effects are
also assumed [27]. Previous studies suggested a multiple mecha-
nism in the mode of action of OTA; however one of the most
pronounced adverse impacts seems to be its very strong ATP
depleting effect [27]. To our current knowledge there has not been
reported any substance to be suitable to alleviate the negative
effect of OTA on ATP synthesis.
In our present study 17 different ﬂavonoid aglycones were
examined from the ﬂavone, ﬂavonol, ﬂavanone, ﬂavanol and
izoﬂavone molecular groups (Fig. 1) to explore their inﬂuence on
intracellular ATP levels in MDCK kidney-derived cell line using
primarily the luciferin–luciferase ATP dependent bioluminescent
reaction. In agreement with the previous studies most of the
applied ﬂavonoids caused no or only a mild decrease of intracellu-
lar ATP concentrations [5–9]. In contrast, the ﬂavone DIOS exerted
a signiﬁcant increase in ATP levels therefore, our experiments werefocused on the investigation of this aglycone. In order to conﬁrm
our observation ATP/ADP ratios were also determined using
HPLC-UV technique. Furthermore, different enzyme inhibitors
were applied to get more information on the observed impact of
DIOS; and the effect of DIOS on mitochondrial oxygen consumption
was also tested using rat liver mitochondria. Finally, combined
treatment of MDCK cells with OTA and DIOS was studied. Our
results showed a considerable elevation of intracellular ATP levels
after short (6–12 h) incubations with micromolar DIOS concentra-
tions (5–15 lM) that fell to the control level after 24 h. Using the
above described techniques we could not determine the exact
mechanism of action of DIOS. Because of the very diverse biochem-
ical effects of DIOS further extensive investigations should be
performed. On the other hand, we could clearly show that DIOS
was suitable to offset OTA-mediated ATP depletion and was even
able to completely restore ATP levels in MDCK cells.2. Materials and methods
2.1. Chemicals
All chemicals and reagents were of analytical grade. Diosmetin
(DIOS), acacetin, hesperetin (from Extrasynthese), apigenin, chry-
sin, myricetin, quercetin (from Fluka), daidzein, luteolin (from
Indoﬁne), baicalein, catechin, ﬁsetin, ﬂavone, galangin, genistein,
morin, naringenin, ochratoxin A (OTA), Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) – high glucose (4500 mg/L), fetal bovine serum
(FBS), oligomycin A (OmA), 3-bromopyruvic acid (3-BP), bovine
serum albumin (BSA), adenosine 50-triphosphate (ATP), adenosine
diphosphate (ADP), penicillin/streptomicyn solution, trypsin
solution, sodium dodecyl sulfate (SDS), Triton X 100 (all from Sig-
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phenylmethylsulfonyl ﬂuoride (PMSF) and ﬂuorescamine (from
Serva), calcein aceoxymethyl ester (CAM) and 6-carboxy-20,70-
dichlorodihydroﬂuorescein diacetate (C400; from Invitrogen) were
used as received. 2000 lM ﬂavonoid and 5000 lM OTA stock solu-
tions were prepared in 96% ethanol (from Reanal, spectroscopic
grade) and kept at 4 C protected from light.
2.2. Instrumentation
Hitachi F-4500 ﬂuorescence spectrophotometer and Berthold
Lumat LB9507 luminometer were used for ﬂuorescent and lumi-
nescent experimentations. Measurements were done in the pres-
ence of air at room temperature. Promega GloMax-Multi
Microplate Multimode Reader was used for ROS-measurements.
Chromatographic analysis of ATP/ADP concentrations was per-
formed on a Dionex Ultimate 3000 (Dionex Corp., Sunnyvale, CA,
USA) analytical HPLC system composed of a binary gradient pump
(HPG-3200SD), an autosampler (WPS-3000RS), a thermostatted
column compartment (TCC-3000RS) and a UV/VIS multiple wave-
length detector (MWD-3000RS).
2.3. Tissue cultures
MDCK (cocker spaniel, kidney, immortalized, ATCC: CCL 34) and
HepG2 (human, liver, hepatocellular carcinoma, ATCC: HB-8065)
adhering cells were cultured in DMEM (high glucose) with 10%
FBS plus penicillin (100 U/ml) and streptomycin (100 lg/ml) in
25 cm2 sterile plastic ﬂasks (VWR) and in 96-well sterile plastic
plates (VWR). Cells were kept at 37 C in the presence of 5% CO2
in humidiﬁed atmosphere. Cells were cultured for 2 days in ﬂasks
then trypsinized and resuspended. 2 ⁄ 104 MDCK cells and
1 ⁄ 104 HepG2 cells per well were dished out to 96-well plates
(150 lL medium/well, counted with a Bürker-type chamber). After
16 h the medium was replaced and the incubation was started
using 5–15 lM ﬂavonoid concentrations. Samples were obtained
and analyzed after 6, 12 and 24 h incubations. All sterile work
was carried out in an Aireguard-126300 (Nuaire) vertical laminar
box.
2.4. Bioluminescent ATP determination
Intracellular ATP concentrations were quantiﬁed using lucif-
erin–luciferase bioluminescent reaction. Sample preparation, mea-
surements and data analysis were done using the previously
published method [28] without modiﬁcations applying internal
standardization. After subjecting cells to the appropriate treat-
ments, cells were washed twice with cold PBS (150 lL) thereafter
150 lL lysis buffer (0.2 M borate buffer, 10 mMMgSO4, 0.1% Triton
X 100, pH 9.2) was added to the wells and the plates were kept at
room temperature for 15 min. 50 lL cell lysates were pipetted into
75 ⁄ 12 mm disposable plastic cuvettes (Sarstedt) containing
100 lL luciferin–luciferase reagent and 850 lL ATP measuring buf-
fer (0.1 M TRIS–acetate buffer, 10 mMMgSO4, 2 mMNa2EDTA, 0.1%
Triton X 100, pH 7.75).
2.5. Determination of ATP/ADP ratio by HPLC-UV
To further verify our results a distinct ATP extraction method
and instrumentation were also applied. First the medium was
removed and cells were washed twice with 150 lL ice-cold PBS
then 100 lL 10% cold (4 C) perchloric acid solution was added to
the system. After incubation (5 min. on ice) every 80 lL extract
was neutralized with 24 lL 20% KOH solution (with 1.5 M
K2HPO4) and incubated for 2 min. on ice. Then samples were
centrifuged (4 C, 10000 RPM, 5 min) to get rid of the resultingpotassium perchlorate precipitate. 40 lL from the supernatant
was injected to the instrument. The separation of ADP and ATP
was carried out according to the method described by Kochanow-
ski et al. [29] with some modiﬁcations. Buffer ‘‘A’’ was prepared by
adding 8 mM of tetrabutylammonium bisulfate (Sigma–Aldrich) to
100 mM potassium phosphate (Spectrum 3D) buffer (pH 6.5),
while buffer ‘‘B’’ was constructed using 70% buffer ‘‘A’’ and 30%
methanol (Molar Chemicals). Both buffers were ﬁltered on
0.2 lm ﬁlters (Merck) prior to use. Separation was carried out at
40 C on a Supelco Discovery C18 column (150  4.6 mm, 5 lm
particle size; Sigma–Aldrich) with a ﬂow rate of 1 ml/min. The gra-
dient proﬁle was shortened compared to the method of Kochanow-
ski et al. [29] according to the following description: from 0 to
5 min 100% ‘‘A’’, then from 5 to 20 min a linear raise of ‘‘B’’ to
77%, and from 20.5 to 28 min 100% ‘‘A’’ again to achieve column
re-equilibration. All chromatograms were analyzed at 254 nm.
2.6. Determination of total protein concentrations with ﬂuorescamine
reagent
Our previously published method was used for total protein
measurements without modiﬁcations [28]. Both ATP detection (ly-
sis with Triton-borate buffer) and intracellular protein determina-
tion were performed from the same well. To prevent proteolysis
the lysis buffer was completed with 0.2 mM PMSF. 75 lL lysates
were added to 2000 lL borate buffer (0.2 M, pH 9.2) thereafter
50 lL ﬂuorescamine solutions (10 mM; in DMSO) were vortexed
into the samples. Fluorescence emission intensities were deter-
mined at 475 nm (kexc = 394 nm), then BSA-standardized total pro-
tein concentrations were calculated.
2.7. Calcein viability assay
Calcein acetoxymethyl ester (CAM) viability assays were per-
formed based on our previously published method without modi-
ﬁcations [28]. After two washing steps with 150 lL PBS cells were
treated with 150 lL CAM solution/well (1.6 lM CAM in PBS) and
incubated for 60 min at 37 C in the dark. Then the mediumwas re-
moved and cells were washed twice with PBS. Thereafter 150 lL
lysis buffer (0.1% SDS in PBS) was added to each well and incubated
for 10 min at room temperature. 100 lL cell lysates were added to
2000 lL PBS then ﬂuorescence emission intensities were deter-
mined (kexc = 480 nm, kem = 515 nm).
2.8. Investigation with enzyme inhibitors
In order to obtain more information on the mechanism of action
of DIOS, enzyme inhibitors were applied: sodium ﬂuoride (NaF) is a
known inhibitor of enolase enzyme therefore it obstructs glycoly-
sis, 3-bromopyruvic acid (3-BP) inhibits both hexokinase and pyru-
vate dehydrogenase enzymes [30,31], ﬁnally oligomycin A (OmA)
inhibits the FO part of ATP synthase. Cells were treated with
10 lMDIOS in the absence and in the presence of different enzyme
inhibitors for 12 h using the previously described conditions (Sec-
tion 2.3.).
2.9. Isolation of rat liver mitochondria and determination of its oxygen
consumption
Wistar rats were purchased from Charles River Hungary Breed-
ing Ltd. The animals were kept under standardized conditions; tap
water and rat chow were provided ad libitum. Animals were
treated in compliance with approved institutional animal care
guidelines. Rat liver mitochondria were prepared by the previously
described standard protocol [32]. Liver was squeezed through a
liver press. All isolated mitochondria were puriﬁed by Percoll
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was assessed by a Clark type oxygen microelectrode. The mito-
chondrial respiration was measured in the presence of different
concentrations of DIOS applying the previously published protocol
[34]. Results were assessed from the original registration curve.
2.10. Determination of intracellular ROS levels
Intracellular ROS levels were determined using the oxidation-
sensitive 6-carboxy-20,70-dichlorodihydroﬂuorescein diacetate
(C400) ﬂuorescent dye. C400 is an acetylated ﬂuorescein
derivative; the non-ﬂuorescent molecule is converted to ﬂuores-
cent form by intracellular esterases and oxidation by ROS which
occurs inside the cells [35,36]. After subjecting cells to the appro-
priate treatment, cells were treated with 4 lM C400 for 2 h at
37oC. Fluorescence measurement was performed on a Promega
GloMax-Multi Microplate Multimode Reader, using 490/510–
570 excitation/emission wavelengths.
2.11. Statistics
All experiments were repeated at least three times. Values are
presented as means ± SD. Statistical analyses were performed with
One-Way ANOVA using IBM SPSS Statistics software (Version 20).
P < 0.05 was set as the level of signiﬁcance.Fig. 2. ATP/total protein levels (in percentage, compared to the control) of MDCK
cells after 12-h (above) and 24-h (below) treatment with 10 lM ﬂavonoid
aglycones (P < 0.05). After 12-h incubation only DIOS showed signiﬁcant elevation
of ATP levels furthermore ﬁsetin and naringenin resulted in the signiﬁcant decrease
of ATP (a). Following 24-h treatment most of the ﬂavonoids caused signiﬁcant
reduction of intracellular ATP while luteolin resulted in elevated ATP/protein ratio
(b). [ctrl = control; ACA = acacetin; API = apigenin; BAI = baicalein; CAT = catechin;
CHRY = chrysin; DAI = daidzein; DIOS = diosmetin; FIS = ﬁsetin; FLA = ﬂavone;
GAL = galngin; GEN = genistein; HES = hesperetin; LUT = luteolin; MOR = morin;
MYR = myricetin; NAR = naringenin; QUE = quercetin].3. Results and discussion
3.1. Effects of ﬂavonoid aglycones on ATP levels of MDCK cells
First the effects of 17 different ﬂavonoid aglycones were exam-
ined on intracellular ATP levels in MDCK cells applying 10 lM agly-
cone concentration and 12-h incubation time. Fig. 2a shows that
among the tested ﬂavonoids only DIOS caused signiﬁcant elevation
of ATP concentrations after 12-h treatment. Furthermore, minor
(non-signiﬁcant) increase of ATP was caused by apigenin. As
Fig. 1 demonstrates there is some structural homology between
DIOS and apigenin: both derivatives belong to the ﬂavone molecu-
lar group (presence of 2,3-double bound and absence of 3-hydroxyl
group) and possess the 5- and 7-hydroxyl groups. On the other
hand, apigenin does not present the 30-hydroxyl and 40-methoxy
substituent in ring B, but possesses the 40-hydroxyl moiety. Inter-
estingly, ﬂavonoids possessing the 40-O-methyl structure (e.g.
acacetin) or more hydroxyl groups in ring B (e.g. luteolin) did not
show the positive effect on ATP levels under the applied condi-
tions. The other aglycones caused no signiﬁcant effect or only mild
decrease (ﬁsetin and naringenin) of ATP levels during the 12-h
incubation period (Fig. 2a).
Thereafter, in a new series of experiments MDCK cells were
treated again with 10 lM ﬂavonoid concentration under the same
conditions except that the incubation time in this case was 24 h.
While acacetin, apigenin and diosmetin did not cause remarkable
changes in ATP levels, other aglycones – with the exception of lute-
olin – resulted in a signiﬁcant decrease of ATP/protein ratio com-
pared to that of the control (Fig. 2b). Baicalein, catechin,
daidzein, ﬂavone, galangin, genistein, hesperetin, morin, myricetin,
naringenin and quercetin caused similar effect: about 25–30%
reduction of ATP levels was observed. Chrysin resulted in lower
(16%) while ﬁsetin caused higher (46%) decrease of ATP than the
above listed ﬂavonoid aglycones. These results are in accordance
with the previous investigations discussed in the introductory sec-
tion [5–9]. Interestingly, after 24-h treatment a signiﬁcant eleva-
tion (about 20%) of ATP levels was caused by luteolin. As it will
be discussed also in the next part (Section 3.2.), the effect of DIOS
is of short duration: in the case of 24-h treatment cellular ATPlevels return to the control value. It is clearly seen in Fig. 1 that
the only difference between DIOS and luteolin is the 40-O-methyl
moiety. Previous studies showed that DIOS can be metabolized to
luteolin in liver cells both in vitro and in vivo, the demethylation
is catalyzed by CYP1 isoenzymes [37,38]. On the other hand, recent
in vivo investigations highlighted that luteolin is a substrate of the
catechol-O-methyl transferase (COMT) enzyme and interestingly
the most preferable reaction is its 40-O-methylation which results
in the formation of DIOS [39,40]. Since the activity of COMT en-
zyme in epithelial tubular kidney cells is high [41] and because
luteolin did not increase ATP levels during 12-h treatment of
MDCK kidney cells we hypothesize that the delayed (compared
to DIOS) effect of luteolin on the ATP system is caused by the
formation of its metabolic product DIOS.3.2. Effects of ﬂavone diosmetin on ATP levels and viability of MDCK
cells
Based on the above described observations our attention was
focused on ﬂavone DIOS. To investigate the concentration and time
dependence of the observed impact cells were treated with 5, 10
and 15 lM DIOS concentrations and ATP levels were determined
after 6, 12 and 24-h incubations (Fig. 3). After 6-h treatment, a dose
dependent elevation of intracellular ATP/protein ratios was
observed: Even 5 lM DIOS led to 16% increase and higher
Fig. 3. ATP/total protein levels (in percentage, compared to the control) of MDCK cells after 6- (left), 12- (middle) and 24-h (right) treatment with 5, 10 and 15 lM DIOS
concentrations, respectively (P < 0.05). Data represent that DIOS caused a dose- and time-dependent elevation of cellular ATP concentration. The effect is relatively short
(6–12 h): after 24-h the ATP levels returns to the control value. [ctrl = control; EtOH = ethanol; DIOS = diosmetin].
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and 28%, respectively). Following 12-h incubation 5 lM DIOS did
not inﬂict signiﬁcant changes compared to the control. On the
other hand, 23% increase was obtained at 10 lM DIOS concentra-
tion. 15 lM DIOS did not cause further elevation of ATP levels
(compared to that of 10 lM concentration). After 24-h treatment
ATP levels were fallen down to the values obtained for controls
for all three DIOS concentrations. Total protein contents and the
results of calcein viability assay did not show signiﬁcant differ-
ences compared to values of the controls at the applied conditions
(data not shown), indicating that the number of living MDCK cells
did not change during DIOS treatment. Thus, our results
highlighted that under these circumstances DIOS was able to
signiﬁcantly elevate intracellular ATP levels, in a dose- and time-
dependent manner; furthermore, no viability loss of MDCK cells
was observed during these experiments.
3.3. Effects of diosmetin on ATP levels and ATP/ADP ratios of MDCK
cells (HPLC)
After quantiﬁcation of intracellular ATP levels with luciferin–
luciferase reaction (using detergent ATP extraction method), inFig. 4. ATP concentrations (left) and ATP/ADP ratios (right) after 12-h incubation of MD
determined by HPLC-DAD after perchloric acid extraction (detailed in the text). The s
agreement with the results from the luciferin–luciferase ATP assay. [ctrl = control; DIOSorder to verify our results and to determine the ATP/ADP ratios,
conﬁrmatory measurements were performed with HPLC using per-
chloric acid for the extraction. MDCK cells were treated with
10 lM DIOS and after 12-h treatment ATP and ADP concentrations
were quantiﬁed by HPLC-DAD system. Results are shown in Fig. 4
where determined ATP levels and ATP/ADP ratios of both the
control and of the treated cells were expressed. These data are in
good agreement with the results obtained from bioluminescent
ATP determination: Signiﬁcant increase of ATP concentration and
considerable elevation of ATP/ADP ratio were observed.
3.4. Effects of ﬂavone diosmetin on the ATP levels and viability of
HepG2 cells
Thereafter to test the observed effect on a different cell line,
additional measurements were performed using HepG2 liver can-
cer cells. Similarly to the MDCK cell line the elevation of ATP/pro-
tein ratios were detected after DIOS treatment. On the other hand
it is important to note that a decrease of cell viability was also
observed even in the case of lower DIOS concentrations based on
total protein and calcein assays, suggesting a negative effect of
DIOS on HepG2 cells. After 12-h incubation with 5–10 lM DIOSCK cells in the absence and in the presence of 10 lM DIOS (P < 0.05). Data were
igniﬁcant elevation of both ATP and ATP/ADP levels were observed which are in
= diosmetin].
Fig. 5. ATP/total protein levels (left) and data for calcein assay (right) of HepG2 liver cells after 24-h treatment with 5–10 lM DIOS concentrations (P < 0.05). 7.5 and 10 lM
DIOS resulted in the signiﬁcant elevation of cellular ATP levels, on the other hand considerable decrease of cell viability was also observed. [ctrl = control; DIOS = diosmetin].
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observed. On the other hand, 7.5 and 10 lM DIOS caused a signif-
icant increase of ATP/protein ratios (18% and 32%, respectively)
while considerable decrease of cell viability was also detected
(15 and 20%, respectively) after 24-h treatment. Fig. 5 shows the
determined values of ATP/protein ratio and calcein ﬂuorescence
after 24-h treatment with 5–10 lM DIOS. Total protein levels were
in good correlation with calcein measurements (data not shown).
There could be several explanations for the time difference of the
DIOS-mediated effect between MDCK and HepG2 cells. Although
the cell medium was the same, the uptake kinetics of DIOS to
MDCK and HepG2 cells can be different and other tissue-derived
differences can also play a role. Furthermore, it is possible that
the metabolism of DIOS in HepG2 cells results in the delayed effect
compared to MDCK cells. The decreased viability in HepG2 cells
can be explained by the commonly occurring tumor selective
toxicity of several ﬂavonoids [42–44], since MDCK is an immortal-
ized, whereas HepG2 is a tumor cell line. This idea is supported by
the study of Androutsopoulos et al. [45] where tumor selective
negative effect of DIOS on cell cycle progression and cell prolifera-
tion were reported on breast cancer cells.Fig. 6. ATP concentrations in MDCK cells after 12-h treatment with 10 lM DIOS
alone and co-treated with different enzyme inhibitors (P < 0.05). Applied sodium
ﬂuoride (NaF), 3-bromopyruvate (3-BP) and olygomycin A (OmA) concentration
caused a remarkable decrease of ATP levels. DIOS alone and in the presence of NaF
or 3-BP was able to signiﬁcantly elevate cellular ATP, on the other hand OmA
completely abolished the positive effect of DIOS on ATP system. [ctrl = control;
DIOS = diosmetin].3.5. Effects of enzyme inhibitors on diosmetin-induced ATP elevation
(MDCK cells)
In the next step of experiments different enzyme inhibitors
were applied (using MDCK cells) in order to get more information
on the observed DIOS-induced impact. Fig. 6 shows the measured
ATP concentrations (applying bioluminescent ATP determination)
after a 12-h combined treatment with DIOS and enzyme inhibitors.
Our results show that negative effects of NaF (3 mM) and 3-BP
(80 lM) concentrations on ATP levels were considerably compen-
sated by the simultaneous treatment with 10 lM DIOS. These
observations indicate that the inhibition of glycolysis or citric acid
cycle cannot weaken or abolish the found impact. In contrast,
complete inhibition of DIOS-induced increase of ATP production
was caused by oligomycin A (15 lM) treatment (Fig. 6). These
observations suggest that the positive effect of DIOS may be related
directly or indirectly to the ATP synthase enzyme or to oxidative
phosphorylation.Fig. 7. ATP/total protein levels of MDCK cells after 24-h treatment with OTA alone
and co-treated with 5–15 lM DIOS (detailed in the text; P < 0.05). 15 lM OTA
resulted in considerable decrease (more than 30%) of cellular ATP levels. Co-
treatment with DIOS caused a dose-dependent, signiﬁcant elevation of ATP/ADP
ratio, 15 lM DIOS abolished completely the OTA-mediated ATP loss. [ctrl = control;
OTA = ochratoxin A; DIOS = diosmetin].
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(isolated rat liver mitochondria)
To test the potential involvement of ATP synthase in the action
of DIOS, its effect on rat liver mitochondria was also examined.
Surprisingly, the oxygen consumption of isolated mitochondria
did not show any increase after treatment with 5–15 lM DIOS.
Only higher DIOS concentrations (20 lM or above) resulted in mild
uncoupling effect (data not shown), which is exactly the opposite
of what we expected. Because lower concentrations of DIOS (5–
15 lM) did not increase the oxygen consumption of the isolated
mitochondria we hypothesize that DIOS does not act directly on
the ATP synthase enzyme. The indirect mechanism of DIOS could
be resulted from several actions e.g. the modiﬁcation of the gene
expression or the modulation of different proteins. Since recent
studies highlighted that ﬂavonoids have diverse and very complex
biochemical effects on living cells and organisms [1–4,17–22] fur-
ther extensive investigations are reasonable to conduct in order to
decipher the exact mechanism of action of DIOS.3.7. Diosmetin versus ATP depleting effect of ochratoxin A
Finally, the discovered positive impact of DIOS on the ATP sys-
tem was tested in a model using a mycotoxin, ochratoxin A. The
ATP depleting effect of OTA is not clearly understood yet but pre-
vious studies suggest its inﬂuence on the mitochondrial respiratory
chain caused by the inhibition of mitochondrial phosphate trans-
port and/or the direct effect on the electron transport chain (inhi-
bition of succinate-supported electron activities) [27]. Based on
our preliminary measurements on MDCK cells, low OTA concentra-
tions (5–15 lM) cause major changes on ATP levels at least after
24-h treatment (data not shown). On the other hand, DIOS seems
to be effective under shorter incubation times (6–12 h). Therefore
MDCK cells were treated with 15 lMOTA (in 150 lL medium/well)
and after 12-h incubation the system was supplemented/co-
treated with 0–15 lM DIOS (in 50 lL DMEM/well, without the
replacement of the previous 150 lL medium) and cells were
incubated for further 12 h. Fig. 7 represents that under the appliedFig. 8. ROS/total protein levels of MDCK cells treated with DIOS alone (left) and co-treat
text; P < 0.05). DIOS alone caused milder decrease of ROS levels. However, 15 lM OTA r
the OTA-mediated elevated ROS production but the effect is not so strong, suggesting tha
on ATP system. [ctrl = control; OTA = ochratoxin A; DIOS = diosmetin].conditions 15 lM OTA resulted in about 30% decrease of total pro-
tein-related ATP levels after the 24-h incubation period. Further-
more, all applied DIOS concentrations lead to signiﬁcant
elevation of ATP/protein values of OTA-exposed cells. The impact
is so effective that 15 lM DIOS restore completely the intracellular
ATP levels. Since ATP synthesis can be inﬂuenced by the oxidative
status of the cells [46] antioxidant effect of DIOS was also tested
applying the same conditions. 15 lM OTA caused an about 60% in-
crease of ROS production (Fig. 8). DIOS alone resulted in a mild
reduction of ROS/total protein levels in MDCK cells. In addition,
DIOS caused signiﬁcant but not dramatic decrease of ROS/protein
ratios in co-treated (both OTA and DIOS) cells compared to the
simply OTA-exposed cells. In vitro antioxidant effect of DIOS was
reported in previous studies [47,48]. On the other hand, DIOS has
much lower radical scavenging activity in cell cultures compared
to other ﬂavonoids (e.g. catechin, quercetin or luteolin) [48–50].
It is also supported by the study of Ramyaa and Padma [51] where
OTA-induced oxidative stress was substantially alleviated by
quercetin. However, none of the other tested ﬂavonoids caused
signiﬁcant elevation of ATP levels in OTA-exposed cells (data not
shown). These results suggest that the DIOS-induced effect on
intracellular ATP concentrations is independent from or depends
only slightly on the antioxidant property of the ﬂavonoid. It is also
important to note, that based on the previous studies the ATP-
depleting effect of OTA is resulted from the inhibition of mitochon-
drial respiratory chain but its toxic effect is not related directly to
the ATP synthase enzyme [27,52–54]. On the other hand, DIOS
abolished the negative effect of OTA on ATP system however, the
inhibition of ATP synthase by olygomicin cannot be alleviated by
DIOS. These observations also suggest the important role of ATP
synthase in the action of DIOS but as we previously discussed
the connection is probably indirect.3.8. Conclusions
In our study the effects of ﬂavonoids on cellular ATP levels were
examined. We described for the ﬁrst time the unexpected effect of
DIOS on ATP levels. Our major conclusions are the following: DIOSed with OTA (15 lM) + DIOS (5–15 lM) (right) after 24-h treatment (detailed in the
esulted in about 60% increase of ROS/protein ratio. DIOS was able to slightly reduce
t antioxidative effect of DIOS does not play an important role in the observed effect
8 M. Poór et al. / Journal of Photochemistry and Photobiology B: Biology 132 (2014) 1–9increases intracellular ATP levels both in MDCK and HepG2 cells.
Inhibition of glycolysis or citric acid cycle does not suppress the
observed effect. DIOS-induced elevation of ATP levels is completely
abolished by the inhibition of ATP synthase with oligomycin A.
DIOS is able to reverse the ATP-depleting effect of the mycotoxin,
ochratoxin A. Most probably the DIOS-induced impact on ATP sys-
tem does not originate from to the antioxidant property of DIOS.
Based on our ﬁndings the above described special impacts of DIOS
may be suitable to positively inﬂuence ATP-depletion caused by
some metabolic poisons.Acknowledgements
Our study was supported by PTE ÁOK-KA-2013/15 and PTE
ÁOK-KA-2013/31. Financial support of the Developing Competi-
tiveness of Universities in the South Transdanubian Region project
(SROP-4.2.1.B-10/2/KONV-2010-0002) is highly appreciated.References
[1] B.H. Havsteen, The biochemistry and medical signiﬁcance of the ﬂavonoids,
Pharmacol. Therapeut. 96 (2002) 67–202.
[2] R.J. Korthui, D.C. Gute, Anti-inﬂammatory actions of a micronized, puriﬁed
ﬂavonoid fraction in ischemia/reperfusion, Adv. Exp. Med. Biol. 505 (2002)
181–190.
[3] F. Dajas, Life or death: neuroprotective and anticancer effects of quercetin, J.
Ethnopharmacol. 143 (2012) 383–396.
[4] V.H. Tran, D. Marks, R.K. Duke, M. Bebawy, C.C. Duke, B.D. Roufogalis,
Modulation of P-glycoprotein-mediated anticancer drug accumulation,
cytotoxicity, and ATPase activity by ﬂavonoid interactions, Nutr. Cancer 63
(2011) 435–443.
[5] N. Chinnam, P.K. Dadi, S.A. Sabri, M. Ahmad, M.A. Kabir, Z. Ahmad, Dietary
bioﬂavonoids inhibit Escherichia coli ATP synthase in a differential manner, Int.
J. Biol. Macromol. 46 (2010) 478–486.
[6] B. Li, S.B. Vik, Y. Tu, Theaﬂavins inhibit the ATP synthase and the respiratory
chain without increasing superoxide production, J. Nutr. Biochem. 23 (2012)
953–960.
[7] S. Kanno, A. Tomizawa, T. Ohtake, K. Koiwai, M. Ujibe, M. Ishikawa, Naringenin-
induced apoptosis via activation of NF-jB and necrosis involving the loss of
ATP in human promyeloleukemia HL-60 cells, Toxicol. Lett. 166 (2006) 131–
139.
[8] L. Mathiesen, K.E. Malterud, R.B. Sund, Uncoupling of respiration and inhibition
of ATP synthesis in mitochondria by C-methylated ﬂavonoids fromMyrica gale
L, Eur. J. Pharmac. Sci. 4 (1996) 373–379.
[9] D.J. Dorta, A.A. Pigoso, F.E. Mingatto, T. Rodrigues, I.M.R. Prado, A.F.C. Helena,
S.A. Uyemura, A.C. Santos, C. Curti, The interaction of ﬂavonoids with
mitochondria: effects on energetic processes, Chem. Biol. Interact 152 (2005)
67–78.
[10] E. Tripoli, M. La Guardia, S. Giammanco, D. Di Majo, M. Giammanco, Citrus
ﬂavonoids: molecular structure, biological activity and nutritional properties:
a review, Food Chem. 104 (2007) 466–479.
[11] S. Roowi, A. Crozier, Flavonoids in tropical citrus species, J. Agric. Food Chem.
59 (2011) 12217–12225.
[12] G. Gattuso, C. Caristi, C. Gargiulli, E. Bellocco, G. Toscano, U. Leuzzi, Flavonoid
glycosides in bergamot juice (Citrus bergamia Risso), J. Agric. Food Chem. 54
(2006) 3929–3935.
[13] J. Meirinhos, B.M. Silva, P. Valentão, R.M. Seabra, J.A. Pereira, A. Dias, P.B.
Andrade, F. Ferreres, Analysis and quantiﬁcation of ﬂavonoidic compounds
from Portuguese olive (Olea europaea L.) leaf cultivars, Nat. Prod. Res. 19
(2005) 189–195.
[14] O. Benavente-García, J. Castillo, J. Lorente, A. Ortuno, J.A. Del Rio, Antioxidant
activity of phenolics extracted from Olea europaea L. leaves, Food Chem. 68
(2000) 457–462.
[15] C. Amato, Advantage of a micronized ﬂavonoidic fraction (Daﬂon 500 mg) in
comparison with a nonmicronized diosmin, Angiology 45 (1994) 531–536.
[16] V.S. Savel’ev, A.V. Pokrovskiı˘, S.V. Sapelkin, I.V. Bogachev, I.L. Bogdanets, IA.
Zolotukhin, Micronized diosmin (Detralex) for vein-related trophic ulcers:
European experience, Angiol. Sosud. Khir. 12 (2006) 53–60.
[17] T. Tanaka, H. Makita, K. Kawabata, H. Mori, M. Kakumoto, K. Satoh, A. Hara, T.
Sumida, T. Tanaka, H. Ogawa, Chemoprevention of azoxymethane-induced rat
colon carcinogenesis by the naturally occurring ﬂavonoids, diosmin and
hesperidin, Carcinogenesis 18 (1997) 957–965.
[18] N. Alvarez, V. Vicente, C. Martínez, Synergistic effect of diosmin and
interferon-alpha on metastatic pulmonary melanoma, Cancer Biother.
Radiopharm. 24 (2009) 347–352.
[19] L. Pari, S. Srinivasan, Antihyperglycemic effect of diosmin on hepatic key
enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced
diabetic rats, Biomed. Pharmacother. 64 (2010) 477–481.[20] T. Silambarasan, B. Raja, Diosmin, a bioﬂavonoid reverses alterations in blood
pressure, nitric oxide, lipid peroxides and antioxidant status in DOCA-salt
induced hypertensive rats, Eur. J. Pharmacol. 679 (2012) 81–89.
[21] M.U. Rehman, M. Tahir, A. Quaiyoom Khan, R. Khan, A. Lateef, O.O. Hamiza, F.
Ali, S. Sultana, Diosmin protects against trichloroethylene-induced renal injury
in Wistar rats: plausible role of p53, Bax and caspases, Br. J. Nutr. 110 (2013)
699–710.
[22] M. Tahir, M.U. Rehman, A. Lateef, R. Khan, A.Q. Khan, W. Qamar, F. Ali, O.
O’Hamiza, S. Sultana, Diosmin protects against ethanol-induced hepatic injury
via alleviation of inﬂammation and regulation of TNF-a and NF-jB activation,
Alcohol 47 (2013) 131–139.
[23] D. Cova, L. De Angelis, F. Giavarini, G. Palladini, R. Perego, Pharmacokinetics
and metabolism of oral diosmin in healthy volunteers, Int. J. Clin. Pharmacol.
Ther. Toxicol. 30 (1992) 29–33.
[24] M.A. Campanero, M. Escolar, G. Perez, E. Garcia-Quetglas, B. Sadaba, J.R.
Azanza, Simultaneous determination of diosmin and diosmetin in human
plasma by ion trap liquid chromatography–atmospheric pressure chemical
ionization tandem mass spectrometry: application to a clinical
pharmacokinetic study, J. Pharmac. Biomed. Anal. 51 (2010) 875–881.
[25] A.E. Pohland, S. Nesheim, L. Friedman, Ochratoxin A: a review, Pure Appl.
Chem. 64 (1992) 1029–1046.
[26] S.C. Duarte, A. Pena, C.M. Lino, Ochratoxin A non-conventional exposure
sources – a review, Microchem. J. 93 (2009) 115–120.
[27] D. Ringot, A. Chango, Y.J. Schneider, Y. Larondelle, Toxicokinetics and
toxicodynamics of ochratoxin A, an update, Chem. Biol. Interact. 159 (2006)
18–46.
[28] M. Poór, Y. Li, S. Kunsági-Máté, Z. Varga, A. Hunyadi, B. Dankó, F.R. Chang, Y.C.
Wu, T. K}oszegi, Protoapigenone derivatives: albumin binding
properties and effects on HepG2 cells, J. Photochem. Photobiol. B 124 (2013)
20–26.
[29] N. Kochanowski, F. Blanchard, R. Cacan, F. Chirat, E. Guedon, A. Marc, J.L.
Goergen, Intracellular nucleotide and nucleotide sugar contents of cultured
CHO cells determined by a fast, sensitive, and high-resolution ion-pair RP-
HPLC, Anal. Biochem. 348 (2006) 243–251.
[30] P.N. Lowe, R.N. Perham, Bromopyruvate as an active-site-directed inhibitor of
the pyruvate dehydrogenase multienzyme complex from Escherichia coli,
Biochemistry 23 (1984) 91–97.
[31] M.C. Shoshan, 3-Bromopyruvate: targets and outcomes, J. Bioenergy
Biomembr. 44 (2012) 7–15.
[32] W.C. Schneider, G.H. Hageboom, Further studies on the distribution of
cytochrome c in rat liver homogenates, J. Biol. Chem. 183 (1950) 123–128.
[33] N.R. Sims, Rapid isolation on metabolically active mitochondria from rat brain
and subregions using Percoll density gradient centrifugation, J. Neurochem. 55
(1990) 698–707.
[34] A. Elimadi, D. Morin, E. Albengres, A.M. Chauvet-Monges, V. Allain, A. Crevat,
J.P. Tillement, Differential effects of zidovudine and zidovudine triphosphate
on mitochondrial permeability transition and oxidative phosphorilation, Br. J.
Pharmacol. 121 (1997) 1295–1300.
[35] W. Jakubowski, G. Bartosz, 2,7-dichloroﬂuorescin oxidation and reactive
oxygen species: what does it measure?, Cell Biol Int. 24 (2000) 757–760.
[36] A. Grzelak, B. Rychlik, G. Bartosz, Light-dependent generation of reactive
oxygen species in cell culture media, Free Radic. Biol. Med. 30 (2001) 1418–
1425.
[37] V. Androutsopoulos, N. Wilsher, R.R. Arroo, G.A. Potter, Bioactivation of the
phytoestrogen diosmetin by CYP1 cytochromes P450, Cancer Lett. 274 (2009)
54–60.
[38] V.P. Androutsopoulos, D.A. Spandidos, The ﬂavonoids diosmetin and luteolin
exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-
catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation, J.
Nutr. Biochem. 24 (2013) 496–504.
[39] Z. Chen, M. Chen, H. Pan, S. Sun, L. Li, S. Zeng, H. Jiang, Role of catechol-O-
methyltransferase in the disposition of luteolin in rats, Drug Metab. Dispos. 39
(2011) 667–674.
[40] Z. Chen, S. Kong, F. Song, L. Li, H. Jiang, Pharmacokinetic study of luteolin,
apigenin, chrysoeriol and diosmetin after oral administration of Flos
Chrysanthemi extract in rats, Fitoterapia 83 (2012) 1616–1622.
[41] P.T. Männistö, S. Kaakkola, Catechol-O-methyltransferase (COMT):
biochemistry, molecular biology, pharmacology, and clinical efﬁcacy of the
new selective COMT inhibitors, Pharmacol. Rev. 51 (1999) 593–628.
[42] W.M. Alarif, A. Abdel-Lateff, A.M. Al-Abd, S.A. Basaif, F.A. Badria, M. Shams, S.E.
Ayyad, Selective cytotoxic effects on human breast carcinoma of new
methoxylated ﬂavonoids from Euryops arabicus grown in Saudi Arabia, Eur.
J. Med. Chem. 66 (2013) 204–210.
[43] F. Hakimuddin, G. Paliyath, K. Meckling, Selective cytotoxicity of a red grape
wine ﬂavonoid fraction against MCF-7 cells, Breast Cancer Res. Treat. 85
(2004) 65–79.
[44] A. Hunyadi, A. Martins, B. Danko, F.R. Chang, Y.C. Wu, Protoﬂavones: a class of
unusual ﬂavonoids as promising novel anticancer agents, Phytochem. Rev.
(2013), http://dx.doi.org/10.1007/s11101-013-9188-2.
[45] V.P. Androutsopoulos, S. Mahale, R.R. Arroo, G. Potter, Anticancer effects of the
ﬂavonoid diosmetin on cell cycle progression and proliferation of MDA-MB
468 breast cancer cells due to CYP1 activation, Oncol. Rep. 21 (2009) 1525–
1528.
[46] Z.T. Schafer, A.R. Grassian, L. Song, Z. Jiang, Z. Gerhart-Hines, H.Y. Irie, S. Gao, P.
Puigserver, J.S. Brugge, Antioxidant and oncogene rescue of metabolic defects
caused by loss of matrix attachment, Nature 461 (2009) 109–113.
M. Poór et al. / Journal of Photochemistry and Photobiology B: Biology 132 (2014) 1–9 9[47] P. Villa, D. Cova, L. De Francesco, A. Guaitani, G. Palladini, R. Perego, Protective
effect of diosmetin on in vitro cell membrane damage and oxidative stress in
cultured rat hepatocytes, Toxicology 73 (1992) 179–189.
[48] I. Morel, G. Lescoat, P. Cogrel, O. Sergent, N. Pasdeloup, P. Brissot, P. Cillard, J.
Cillard, Antioxidant and iron-chelating activities of the ﬂavonoids catechin,
quercetin and diosmetin on iron-loaded rat hepatocyte cultures, Biochem.
Pharmacol. 45 (1993) 13–19.
[49] S.R. Husain, J. Cillard, P. Cillard, Hydroxyl radical scavenging activity of
ﬂavonoids, Phytochemistry 26 (1987) 2489–2491.
[50] A. Seyoum, K. Asres, F.K. El-Fiky, Structure-radical scavenging activity
relationships of ﬂavonoids, Phytochemistry 67 (2006) 2058–2070.[51] P. Ramyaa, V.V. Padma, Ochratoxin-induced toxicity, oxidative stress and
apoptosis ameliorated by quercetin – modulation by Nrf2, Food Chem. Toxicol.
62 (2013) 205–216.
[52] M.D. Aleo, R.D. Wyat, R.G. Schnellmann, Mitochondrial dysfunction is an early
event in ochratoxin A but not oosporein toxicity to rat renal proximal tubules,
Toxicol. Appl. Pharmacol. 107 (1991) 73–80.
[53] H. Meisner, S. Chan, Ochratoxin A, an inhibitor of mitochondrial transport
systems, Biochemistry 13 (1974) 2795–2800.
[54] Y.H. Wei, T.N. Lu, R.D. Wei, Effect of ochratoxin A on rat liver mitochondrial
respiration and oxidative phosphorilation, Toxicology 36 (1985) 119–123.
